2-Imidazol-1-yl-4-pyrrolidin-1-yl-pyrimidine | 138609-98-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Imidazol-1-yl-4-pyrrolidin-1-yl-pyrimidine
• 英文别名: 2-Imidazol-1-yl-4-pyrrolidin-1-ylpyrimidine
• CAS: 138609-98-0
• 化学式: C₁₁H₁₃N₅
• 分子量: 215.258
• InChiKey: LVOVQAAKHMHDCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  咪唑 、 2-氯-4-(吡咯啉-1-基)嘧啶 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-Imidazol-1-yl-4-pyrrolidin-1-yl-pyrimidine
  参考文献：
  名称：

  Synthesis and in vitro study of platelet antiaggregant activity of 2(4)-imidazol-1-yl-4(2)-cycloalkylamino pyrimidines

  摘要：

  The synthesis of some 2(4)-imidazol-1-yl-4(2)-cycloalkylaminopyrimidines are reported. The compounds demonstrated a marked antiaggregating activity superior to dipyridamole, ASA, ticlopidine and similar to that of indobufen.

  DOI：

  10.1016/0223-5234(91)90123-5

文献信息

• SUBSTITUTED 4-(1-PYRROLIDINYL)PYRIMIDINE COMPOUNDS AS DIMERIZATION INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE
  申请人：Northwestern University

  公开号：US20200377481A1

  公开（公告）日：2020-12-03

  Disclosed are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. The disclosed compounds may be described as substituted 4-(1-pyrrolidinyl)pyrimidine compounds. The disclosed compounds are shown to inhibit the activity of nitric oxide synthases (NOSs) including neuronal NOS (nNOS) by inhibiting dimerization, and as such, the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with nNOS activity.
• Synthesis and in vitro study of platelet antiaggregant activity of 2(4)-imidazol-1-yl-4(2)-cycloalkylamino pyrimidines
  作者：L Del Corona、G Signorelli、S Manzardo、A Pinzetta、G Coppi

  DOI：10.1016/0223-5234(91)90123-5

  日期：1991.10

  The synthesis of some 2(4)-imidazol-1-yl-4(2)-cycloalkylaminopyrimidines are reported. The compounds demonstrated a marked antiaggregating activity superior to dipyridamole, ASA, ticlopidine and similar to that of indobufen.